31 results about "Plasma Metabolism" patented technology

The invention discloses a blood plasma metabolic marker related to the diagnosis of Tourette syndrome (TS) in children and its application. The markers are L-arginine and D-pipericolic acid. The markers of the present invention can diagnose the risk of TS in children from the perspective of metabolites, and the results are accurate, objective and reliable, can well distinguish the TS group from the normal group, can accurately and sensitively evaluate the risk of TS, and only need to provide blood samples It can be carried out without other tissue samples, greatly improving the possibility and feasibility of clinical application, and providing guidance for clinicians to formulate early diagnosis and intervention plans.

The invention discloses a method for analyzing plasma metabolomics of patients with primary osteoporosis based on sleep disorders. The samples are prepared and collected from the plasma samples of primary osteoporosis patients with sleep disorders treated by sleep cognitive behavior. Then prepare for ultra-high performance liquid chromatography-mass spectrometry detection and analysis; sleep disorders are determined according to the Pittsburgh sleep quality index scale; ultra-high performance liquid chromatography-mass spectrometry detection and analysis: serum samples are separated by chromatographic columns and analyzed by mass spectrometry; data analysis Extract and align the original data of the instrument to obtain data that is free from noise interference and can be used for statistical analysis. Analyze the data through orthogonal partial least squares discriminant analysis and paired sample T test to obtain the differential metabolites between the two groups, and Preliminary identification and verification of these substances combined with existing literature reports. The present invention provides favorable technical support for the early prediction and prognosis of patients with primary osteoporosis in sleep disordered groups.

The invention belongs to the technical field of biomedicine, and specifically relates to a plasma metabolic marker for distinguishing benign and malignant ovarian tumors and an application thereof. The present invention provides a new combination of plasma diagnostic markers for distinguishing benign and malignant (borderline + malignant) ovarian tumors, and can also be used to distinguish benign and early malignant ovarian tumors (borderline + malignant), with high accuracy and sensitivity High characteristics, the AUC of the training set reached 0.876, and the AUC of the verification set was 0.896. The AUC of the early diagnosis training set is 0.847, and the AUC of the verification set is 0.988, which is better than that of CA125 (AUC: training set: 0.733; verification set: 0.893). The marker combination belongs to plasma small molecule metabolites and has the advantage of being non-invasive.

The invention discloses a metabolomics-based diagnostic marker for pancreatic cancer and a screening method thereof. The diagnostic marker comprises any one or a combination of 31 plasma metabolic markers. The present invention also provides a method for constructing a diagnostic model using the pancreatic cancer diagnostic marker and its application in a diagnostic kit. The present invention conducts non-target metabolomics analysis on patient plasma through high-performance liquid chromatography-mass spectrometry technology, discovers differential metabolites between pancreatic cancer patients and normal people through artificial intelligence data analysis technology, and further analyzes target metabolomics and Machine learning modeling verifies the diagnostic ability of the specific differential metabolites, namely pancreatic cancer diagnostic markers, in the diagnosis of pancreatic cancer.

The invention discloses a group of plasma metabolism micromolecular markers related to lung cancer early diagnosis and an application thereof. The plasma metabolism micromolecular markers comprise oneor more of the following markers: propionic acid, aspartic acid, furan glucoside, citric acid, allose, talose, galactopyranose, pyruvic acid, tryptophan, leucyl proline, glyceryl phosphoryl choline,oleoyl carnitine, lysophosphatidyl choline (18:3), lysophosphatidyl choline (18:2), lysophosphatidyl choline (18:1), lysophosphatidyl choline (22:6), lysophosphatidyl ethanolamine (20:0), lysophosphatidyl ethanolamine (18:2), and complex aminoacyl valine. Compared with the traditional protein biomarkers, the group of the provided markers has the stronger outcome relevance with diseases, and is stable, minimally invasive, and easy to detect, capable of greatly improving the sensitivity and the specificity of the related disease diagnosis, and suitable for the early clinical diagnosis and monitoring of lung cancer.

The invention belongs to the field of medical biotechnology and relates to the application of plasma metabolic markers in diagnosing or monitoring HBV. The object of the present invention is to provide the application of the metabolic marker in the blood in the preparation diagnosis or the reagent of monitoring hepatitis B virus, wherein, said marker is Creatinine, L-Proline, L-Arginine, PC (P-16: 0 / 20:4(8Z, 11Z, 14Z, 17Z)), PE(18:2(9Z, 12Z) / 18:1(9Z)), PC(o‑16:1(9Z) / 18:2( 9Z,12Z)), PC(P-16:0 / 18:1(11Z)), PE(18:2(9Z,12Z) / 18:0), PE(P-16:0 / 22:4( 7Z,10Z,13Z,16Z)), PE(P-16:0 / 22:4(7Z,10Z,13Z,16Z)), PE(P-18:0 / 18:2(9Z,12Z)), PE(18:0 / 18:1(11Z)), LysoPE(18:0 / 0:0), PE(16:0 / 18:1(11Z)), or PE(18:2(9Z, 12Z) / 16:0).

The invention concretely relates to a method for simultaneously detecting paracetamol and its eight blood plasma metabolites. An experiment result shows that the method allows the lower quantification limit of the paracetamol and its eight blood plasma metabolites to reach 0.46 ng / mL, and the correlation coefficient of every linear regression equation is 0.998; the intra-day accuracy of all detected substances is 85-111%, and the precision is lower than 9%; and the inter-day accuracy of all the detected substances is 94-108%, and the precision is lower than 9%. The method is fast, sensitive and accurate, and is suitable for quantitatively detecting the paracetamol and its eight blood plasma metabolites in rat blood plasma.

The invention relates to a cholelithiasis related blood plasma metabolism micro-molecular marker and an application thereof. The marker is trimethylamine oxide and trimethylamine. Metabolism micro-molecules of normal contrast blood plasma and cholelithiasis patient's blood plasma are compared through adopting UPLC-Q exactive MS to find the blood plasma metabolism micro-molecular marker combination used for assessing that whether a patient is suffering from cholelithiasis and having diagnosis values in the blood plasma. A cholelithiasis diagnosing and monitoring kit convenient for clinic application is developed through applying the UPLC-Q exactive MS detected by the blood plasma metabolism micro-molecular marker.